FR2901703B1 - USE OF ZATOSETRON FOR THE TREATMENT OF ROSACEA, AND PHARMACEUTICAL COMPOSITIONS - Google Patents

USE OF ZATOSETRON FOR THE TREATMENT OF ROSACEA, AND PHARMACEUTICAL COMPOSITIONS

Info

Publication number
FR2901703B1
FR2901703B1 FR0651984A FR0651984A FR2901703B1 FR 2901703 B1 FR2901703 B1 FR 2901703B1 FR 0651984 A FR0651984 A FR 0651984A FR 0651984 A FR0651984 A FR 0651984A FR 2901703 B1 FR2901703 B1 FR 2901703B1
Authority
FR
France
Prior art keywords
zatosetron
rosacea
treatment
pharmaceutical compositions
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0651984A
Other languages
French (fr)
Other versions
FR2901703A1 (en
Inventor
Jean Dominique Pierret
Fabrizio Folfi
Christian Loesche
Nadege Tremel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0651984A priority Critical patent/FR2901703B1/en
Priority to PCT/FR2007/051361 priority patent/WO2007138233A2/en
Publication of FR2901703A1 publication Critical patent/FR2901703A1/en
Application granted granted Critical
Publication of FR2901703B1 publication Critical patent/FR2901703B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR0651984A 2006-05-31 2006-05-31 USE OF ZATOSETRON FOR THE TREATMENT OF ROSACEA, AND PHARMACEUTICAL COMPOSITIONS Expired - Fee Related FR2901703B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0651984A FR2901703B1 (en) 2006-05-31 2006-05-31 USE OF ZATOSETRON FOR THE TREATMENT OF ROSACEA, AND PHARMACEUTICAL COMPOSITIONS
PCT/FR2007/051361 WO2007138233A2 (en) 2006-05-31 2007-05-31 Use of zatosetron for the treatment of rosacea, and pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0651984A FR2901703B1 (en) 2006-05-31 2006-05-31 USE OF ZATOSETRON FOR THE TREATMENT OF ROSACEA, AND PHARMACEUTICAL COMPOSITIONS

Publications (2)

Publication Number Publication Date
FR2901703A1 FR2901703A1 (en) 2007-12-07
FR2901703B1 true FR2901703B1 (en) 2012-12-07

Family

ID=37663114

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0651984A Expired - Fee Related FR2901703B1 (en) 2006-05-31 2006-05-31 USE OF ZATOSETRON FOR THE TREATMENT OF ROSACEA, AND PHARMACEUTICAL COMPOSITIONS

Country Status (2)

Country Link
FR (1) FR2901703B1 (en)
WO (1) WO2007138233A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942138A1 (en) * 2009-02-16 2010-08-20 Galderma Res & Dev ASSOCIATION OF COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DERMATOLOGICAL DISEASES
KR20120104512A (en) 2009-07-14 2012-09-21 알바니 몰레큘라 리써치, 인크. 5-ht3 receptor modulators, methods of making, and use thereof
FR2960152A1 (en) * 2010-01-27 2011-11-25 Galderma Res & Dev Means limiting the expression of the gene encoding histamine receptor H2 and/or an antagonist of histamine receptor H2 for the treatment of e.g. rosacea, erythematotelangiectatic rosacea and papulopustular rosacea (subtype II)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87674A (en) * 1987-09-08 1993-08-18 Lilly Co Eli Azabicycloalkyl esters and amides of heterocyclic acids, their preparation and pharmaceutical compositions containing them
EP1600158A1 (en) * 2004-05-26 2005-11-30 Galderma Research & Development, S.N.C. Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
WO2007138233A3 (en) 2008-01-24
FR2901703A1 (en) 2007-12-07
WO2007138233A2 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
FR14C0050I1 (en) COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF MULTIPLE SCLEROSIS
FR2907011B1 (en) USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS
CL2013001654A1 (en) Compounds derived from 6-amino-2-phenylamino-1h-benzimidazol-5-carboxamide; pharmaceutical composition; and its use in the treatment and / or prevention of inflammatory diseases and / or associated conditions, in particular pain.
CL2008001076A1 (en) COMPOUNDS DERIVED FROM SULFONAMIDE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2008001002A1 (en) COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION.
BRPI0717697A2 (en) compound, pharmaceutical composition, use of the compound, method of treating a patient suffering from a pathological condition or disease and combination of products
CL2008001003A1 (en) COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION.
CL2007003523A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE ACTIVITY OF PI3 QUINASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE IN THE CANCER PROFILACTIC OR THERAPEUTIC TREATMENT
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
FR2925339B1 (en) DRUG FOR THE TREATMENT OF PANCREATIC CANCER
FR2887450B1 (en) CONCENTRATED INGREDIENT FOR THE TREATMENT AND / OR MODIFICATION OF SURFACES, AND ITS USE IN COSMETIC COMPOSITIONS
BRPI0814957A2 (en) COMPOUND, PRODUCT, PHARMACEUTICAL AGENT, METHOD FOR PROPHYLAXY OR TREATMENT OF A DISEASE, DISORDER OR CONDITION, AND USE OF THE COMPOUND.
CL2007002920A1 (en) COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
FR2900819B1 (en) BIS-UREE TYPE COMPOUND, COMPOSITION COMPRISING SAME, USE AND METHOD OF COSMETIC TREATMENT
CL2007003645A1 (en) PARASITICIDE COMPOUNDS DERIVED FROM SUBSTITUTED ARIL-PIRAZOLES; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT A PARASITARY INFECTION.
BRPI1009781A2 (en) compounds for the treatment of metabolic disorders, pharmaceutical compositions comprising them and their use
FR2910325B1 (en) USE OF LUPULONES FOR THE PREVENTION AND THERAPY OF COLORECTAL CANCER.
CL2007003038A1 (en) COMPOUNDS DERIVED FROM 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
BR112013014189A2 (en) pharmaceutical composition comprising transcinamaldehyde and its use in the treatment of infections
BRPI0720323A2 (en) compound, method of treatment, pharmaceutical composition and use of the compound
FR21C1049I2 (en) PHARMACEUTICAL COMPOSITION COMPRISING CITRATE AND BICARBONATE SALTS, AND ITS USE FOR THE TREATMENT OF CYSTINURIA
EP2056857A4 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
CL2007000850A1 (en) COMPOUNDS DERIVED FROM BENZIMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE TO PREVENT OR TREAT BONE CONDITIONS ASSOCIATED WITH STRONG REDUCTION OR INCREASED CALCIUM RESORTION.
FR2897533B1 (en) OXIDIZING AGENT FOR THE TREATMENT OF HAIR

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140131